Update on the Treatment of Small Cell Lung Cancer and Neuroendocrine Lung Cancers
By: Ronald B Natale, MD
Update on the Treatment of Small Cell Lung Cancer and Neuroendocrine Lung Cancers
By: Ronald B. Natale, MD
Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)
By: Roy S. Herbst, MD, PhD, FACP, FASCO
Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)
By: Roy S. Herbst, MD, PhD, FACP, FASCO
ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?
By: Sai-Hong Ignatius Ou, MD, PhD
ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?
By: Sai-Hong Ignatius Ou, MD, PhD
